Navigation Links
'Heart' of Herschel to be presented to media
Date:9/4/2007

By the end of 2007, the assembly of the ESA's Herschel far-infrared space observatory - the latest mission to study the formation and evolution of stars and galaxies - will be completed.

ESA and Astrium are jointly inviting the media to a press conference in Friedrichshafen, Germany, on 19 September 2007, to hear about this revolutionary spacecraft, its scientific objectives, and to view the very heart of its hardware.

The Herschel mission, equipped with the largest telescope ever launched in space (3.5 m diameter), will give astronomers their best capability yet to explore the universe at far-infrared and sub-millimetre wavelengths. By measuring the light at these wavelengths, scientists see the 'cold' universe. Herschel will give them an unprecedented view, allowing them to see deep into star forming regions, galactic centres and planetary systems.

In order to achieve its objectives and to be able to detect the faint radiation coming from the coolest objects in the cosmos, otherwise 'invisible', Herschel's detectors must operate at very low and stable temperatures. The spacecraft is equipped so as to cool them close to absolute zero (-273.15 C), ranging from -271 C to only a few tenths of a degree above absolute zero. To have achieved this particular feature alone is a remarkable accomplishment for European industry and science.

The final integration of the various components of the Herschel spacecraft - payload module, cryostat, service module, telescope and solar arrays - will be completed in the next few months. This phase will be followed by a series of tests to get the spacecraft ready for launch at the end of July 2008. Herschel will be launched into space on an Ariane 5 ECA rocket. The launch is shared with Planck, ESA's mission to study relic radiation from the Big Bang.


'/>"/>

Contact: ESA Media Relations Office
media@esa.int
33-015-369-7299
European Space Agency
Source:Eurekalert

Page: 1

Related biology news :

1. HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs
2. UCSD team discovers specialized, rare heart stem cells in newborns
3. Implanted Devices Detect High-Risk Heart Failure Patients
4. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
5. Special Imaging Study Shows Failing Hearts Are Energy Starved
6. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
7. Single stem cells from bone heal a broken heart
8. Heart repair gets new muscle
9. Python a hearty eater
10. Columbia study shows widely used artery clearing device does not help patients during heart attack
11. Researchers reveal secret of key protein in brain and heart function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... Linda, Ca (PRWEB) , ... April 27, 2017 ... ... hear from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin D ... that prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... ... LABS, Inc. (LABS) announced in December 2016 that two new Zika ... Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM and IgG ZIKV ... donors under an Investigational New Drug (IND) study protocol. , Now, as part ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
Breaking Biology Technology: